Preview this article 1 min Personalis shareholders will receive $16.25 per share. The deal is expected to close in late 2026 ...

The AI in pathology market is witnessing strong growth, driven by the increasing adoption of digital pathology, rising cancer incidence, and the growing demand for faster and more accurate diagnostic ...

Key Points Interested in Tempus AI, Inc.? Here are five stocks we like better. Tempus AI plans to acquire Personalis to ...

American News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely watched stories in both biotech and technology. Pharmaceutical ...

According to BCC Research, AI is helping medical plastics companies reduce production costs, improve product consistency and accelerate innovation for medical devices and healthcare ...

The AI in drug discovery market is evolving from fragmented, stage-specific applications toward integrated discovery ...

The acquisition builds on an existing partnership and will allow Tempus to advance its cancer monitoring solutions.

Tempus AI Inc. (NASDAQ:TEM) is one of the 10 worst artificial intelligence stocks under $30 according to short sellers. During the first week of June, Tempus AI Inc. (NASDAQ:TEM) shared the impending ...

AI can be added to legacy motion control systems in three phases with minimal disruption: data collection via edge gateways, non-interfering anomaly detection and supervisory control integration.

Seasoned manufacturing professionals know the assets that make their products – the assembly robots, CNC machines, and conveyor belts – are just as important as the final products themselves. These ...